The use of sodium oxybate to treat narcolepsy

Expert Review of Neurotherapeutics

Volumn 12, Issue 5, 2012, Pages 519-529

  Mayer, Geert ^a  

^a Hephata Klinik   (Germany)

Author keywords

cataplexy; excessive daytime sleepiness; flip flop switch; GABA; narcolepsy; sodium oxybate

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; 4 HYDROXYBUTYRIC ACID; CLOMIPRAMINE; GAMMA BUTYROLACTONE; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; VENLAFAXINE;

ANXIETY DISORDER; APNEA HYPOPNEA INDEX; BEDTIME DOSAGE; CATAPLEXY; CONFUSION; DAYTIME SOMNOLENCE; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; NARCOLEPSY; NAUSEA; OFF LABEL DRUG USE; PARASOMNIA; PARESTHESIA; POLYSOMNOGRAPHY; POSTMARKETING SURVEILLANCE; PREGNANCY; QUALITY OF LIFE; RESPIRATION DEPRESSION; RESTLESS LEGS SYNDROME; REVIEW; SIDE EFFECT; SLEEP DISORDER; SLEEP WALKING; SOMNOLENCE; TREMOR; VOMITING; WAKEFULNESS; WEIGHT REDUCTION;

ADJUVANTS, ANESTHESIA; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NARCOLEPSY; QUALITY OF LIFE; SODIUM OXYBATE;

EID: 84860593352     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.42     Document Type: Review

References (79)

1. Laborit G, Larcan A, Kind A. Electrocardiographic study of sodium 4-hydroxybutyrate. Agressologie 4, 77-88 (1963)
2. Broughton R, Mamelak M. Gamma-hydroxybutyrate in the treatment of compound narcolepsy: A preliminary report. In: Narcolepsy. Guilleminault C, Dement WC, Passouant P (Eds). Spectrum Publications, NY, USA, 1-35 (1976)
3. Broughton R, Mamelak M. Effects of nocturnal gamma-hydoxybutyrate on sleep/waking patterns in narcolepsy- cataplexy. Can. J. Neurol. Sci. 7, 23-31 (1980)
4. Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. Gammahydroxybutyrate and narcolepsy: A double-blind placebo-controlled study. Sleep 16, 216-220 (1993)
5. Scrima L, Hartman PG, Johnson FH Jr, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: Double-blind subjective measures. Biol. Psychiatry 26, 331-343 (1989)
6. Scrima L, Hartman PG, Johnson FH. Jr, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: A double-blind study. Sleep 13, 479-490 (1990)
7. Nelson T, Kaufman E, Kline J, Sokoloff L. The extramural distribution of g-hydroxybutyrate. J. Neurochem. 37, 1345-1348 (1981)
8. Okun MS, Boothby LA, Bartfield RB. GHB: An important pharmacological and clinical update. J. Pharm. Pharmaceut. Sci. 4(2), 167-175 (2001)
9. Mamelak M. Gamma-hydroxybutyrate: An endogenous regulator of energy metabolism. Neurosci. Biobehav. Rev. 13(4), 187-198 (1989)
10. Kaufmann EE, Porrino LJ, Nelson T. Pyretic action of low dose of gamma-hydroxy butyrate in rats. Biochem. Pharmacol. 40, 2637-2240 (1990)
11. Snead OC, Liu CC. Gamma-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. Biochem. Pharmacol. 33(16), 2587-2590 (1984)
12. Kaupmann K, Cryan JF, Wellendorph P et al. Specific gamma- hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur. J. Neurosci. 18(10), 2722-2730 (2003)
13. Vienne J, Bettler B, Franken P, Tafti M. Differential effects of GABAB receptor subtypes, (gamma)-hydroxybutyric acid, and baclofen on EEG activity and sleep regulation. J. Neurosci. 30(42), 14194-14204 (2010)
14. Carai MAM, Colombo G, Brunetti G et al. Role of GABA(B) receptors in the sedative/hypnotic effect of g-hydroxybutyric acid. Eur. J. Pharmacol. 428(3), 315-321 (2001)
15. Pardi D, Black J. g-hydroxybutyrate/ sodium oxybate neurobiology, and impact on sleep and wakefulness. CNS Drugs 20(12), 993-1018 (2006)
16. Van Cauter, Plat L, Scharf M et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J. Clin. Invest. 100(3), 745-753 (1997)
17. Donjacour CE, Aziz NA, Roelfsma F et al. Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am. J. Physiol. Endocrinol. Metab. 300(6), E1069-E1075 (2011)
18. Murphy KD, Rose MW, Chinkes DL et al. The effects of gammahydroxybutyrate on hypermetabolism and wound healing in a rat model of large thermal injury. J. Trauma 63(5), 1099-1107 (2007)
19. Gray JA, Goodwin GM, Heal DJ, Green AR. Hypothermia induced by baclofen, a possible index of GABAB receptor function in mice, is enhanced by antidepressant drugs and ECS. Br. J. Pharmacol. 92, 863-870 (1987)
20. García FB, Pedraza C, Arias JL, Navarro JF. Effects of subchronic administration of gammahydroxybutyrate (GHB) on spatial working memory in rats. Psicothema 18(3), 519-524 (2006)
21. Walsh JK, Hall-Porter JM, Griffin KS et al. Enhancing slow-wave sleep with sodium oxybate reduces the behavioral and physiological impact of sleep loss. Sleep 33(9), 1217-1225 (2010)
22. Pardi D, Black JE. Sodium oxybate: Neurobiology and clinical efficacy. Future Neurol. 1(6), 721-735 (2006)
23. Borgen LA, Okerholm R, Morrison D, Lai A. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J. Clin. Pharmacol. 43, 59-65 (2003)
24. Snead OC, Gibson KM. g-hydroxybutyric acid. N. Engl. J. Med. 352, 2721-2732 (2005)
25. Borgen LA, Okerholm RA, Scharf MB. The pharmacokinetics of sodium oxybate following acute and chronic administration to narcoleptic patients. J. Clin. Pharmacol. 44, 253-257 (2004)
26. Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB. Pharmacokinetics of gamma-hydroxybutyrate (GHB) in narcoleptic patients. Sleep 21, 507-514 (1998)
27. Borgen L, Lane E, Lai A. Xyrem (sodium oxybate). A study of dose proportionality in healthy human subjects. J. Clin. Pharmacol. 40, 1053 (2000) (Abstract)
28. US Xyrem Multicenter Study Group. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25(1), 42-49 (2002)
29. The Xyrem International Multicenter Study Group. A double-blind, placebo-controlled study demonstrates the nightly administration of sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J. Clin. Sleep Med. 1, 391-397 (2005)
30. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: A double-blind, placebo-controlled study in 228 patients. Sleep Medicine 6, 415-421 (2005)
31. US Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 26, 31-35 (2003)
32. US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 5, 119-123 (2004)
33. Poryazova R, Tartarotti S, Khatami R et al. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience. Eur. Neurol. 65(3), 175-182 (2011)
34. Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 27(7), 1327-1334 (2004)
35. Black J, Houghton W. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29(7), 939-946 (2006)
36. Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: A double-blind, placebo-controlled study in patients with narcolepsy. J. Clin. Sleep Med. 6(6), 596-602 (2010)
37. Mamelak M, Escriu JM, Stokan O. The effects of gammahydroxybutyrate on sleep. Biol. Psychiatry 12, 273-288 (1977)
38. Meerlo P, Westerveld P, Turek FW, Koehl M. Effects of gammahydroxybutyrate (GHB) on vigilance states and EEG in mice. Sleep 27, 899-904 (2004)
39. Dauvilliers Y, Paquereau J, Bastuji H, Drouot X, Weil JS, Viot-Blanc V. Psychological health in central hypersomnias: The French Harmony study. J. Neurol. Neurosurg. Psychiatry 80(6), 636-641 (2009)
40. Schuld A, Hebebrand J, Geller F, Pollmacher T. Increased body-mass index in patients with narcolepsy. Lancet 355, 1274-1275 (2000)
41. Droogleever Fortuyn HA, Swinkels S, Buitelaar J et al. High prevalence of eating disorders in narcolepsy with cataplexy: A case-control study. Sleep 31(3), 335-341 (2008)
42. Plazzi G, Ferri R, Antelmi E et al. Restless legs syndrome is frequent in narcolepsy with cataplexy patients. Sleep 33(5), 689-694 (2010)
43. Mayer G, Meier-Ewert K. Motor dyscontrol in sleep of narcoleptic patients (a lifelong development?). J. Sleep Res. 2, 143-148 (1993)
44. Dauvilliers Y, Rompre S, Gagnon JF, Vendette M, Petit D, Montplaisir J. REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 30, 844-849 (2007)
45. Knudsen S, Jennum PJ, Alving J, Sheikh SP, Gammeltoft S. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep 33(2), 169-176 (2010)
46. Sansa E, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med. 11(1), 93-95 (2010)
47. Abril B, Carlander B, Touchon J, Dauvilliers Y. Restless legs syndrome in narcolepsy: A side effect of sodium oxybate? Sleep Med. 8(2), 181-183 (2007)
48. Mayer G, Kesper K, Dauvilliers Y, Sonka K, Black J. Muscle activity in sleep of narcoleptic patients treated with sodium oxybate. Presented at: The 25th Annual Meeting of the Associated Professional Sleep Socities (APSS). Minneapolis, MN, USA, 11-15 June 2011 (Abstract)
49. Bosch OG, Quednow BB, Seifritz E, Wetter TC. Reconsidering GHB: Orphan drug or new model antidepressant? J. Psychopharmacol. doi:10.1177/ 0269881111421975 (2011) (Epub ahead of print)
50. Nightingale S, Orgill JC, Ebrahim IO, De Lacy SF, Agrawal S, Williams AJ. The association between narcolepsy and REM behavior disorder (RBD). Sleep Med. 6, 253-258 (2005)
51. Mattarozzi K, Bellucci C, Campi C et al. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy. Sleep Med. 9(4), 425-433 (2008)
52. Ferri R, Franceschini C, Zucconi M et al. Searching for a marker of REM sleep behavior disorder: Submentalis muscle EMG amplitude analysis during sleep in patients with narcolepsy/cataplexy. Sleep 31(10), 1409-1417 (2008)
53. Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med. 10(6), 661-663 (2008)
54. Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): Abuse, misuse, dependence and diversion. J. Clin. Sleep Med. 5(4), 365-371 (2009)
55. Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep 29(9), 1189-1194 (2006)
56. Murali H, Kotagal S. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 29, 1025-1029 (2006)
57. Aran A, Einen M, Lin L, Plazzi G, Nishino S, Mignot E. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: A retrospective study of 51 children. Sleep 33(11), 1457-1464 (2010)
58. Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem®): Differences in characteristics and misuse. Drug Alcohol Depend. 104(1-2), 1-10 (2009)
59. Ristanovic R, Black J, Mamelak M, Montplaisir J. Analysis of dose-effects of sodium oxybate on nocturnal respiratory disturbances. Sleep 24(Suppl.), A473-A474 (2002)
60. Black J, Ristanovic R, Mamelak M, Montplaisir J. Effect of increasing doses of sodium oxybate on nocturnal oxygen saturation: Preliminary findings. Presented at: The 16th Annual Meeting of the Associated Professional Sleep Socities (APSS). Seattle, WA, USA, 10-14 June 2002.
61. Donjacour CE, Aziz NA, Frölich M et al. Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. Eur. J. Endocrinol. 164(3), 363-370 (2011)
62. Seeck-Hirschner M, Baier P, von Freier A, Aldenhoff J, Göder R. Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: Two case reports. Sleep Med. 10,154-155 (2009)
63. Poli F, Ricotta L, Vandi S et al. Catathrenia under sodium oxybate in narcolepsy with cataplexy. Sleep Breath. 16(2), 427-434 (2012)
64. George CFP, Feldman N, Zheng Y et al. A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome. Sleep Breath. 15, 13-20 (2011)
65. Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med. 10(4), 490-493 (2009)
66. Lammers GJ, Bassetti C, Billiard M et al. Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Med. 11, 105-106 (2010)
67. Feldman N. Clinical perspective: Monitoring sodium oxybate treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath. 14, 77-79 (2010)
68. Ferrara SD, Tedeschi L, Frison G, Rossi A. Fatality due to gammahydroxybutyric acid (GHB) and heroin intoxication. J. Forensic Sci. 40, 501-504 (1995)
69. Billiard M, Bassetti C, Dauvilliers Y et al. EFNS guidelines on management of narcolepsy. Eur. J. Neurol. 13(10), 1035-1048 (2006)
70. Morgenthaler TI, Kapur VK, Brown T et al. Standards of Practice Committee of the AASM. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30(12), 1705-1711 (2007)
71. Nimmerrichter AA, Walter H, Guiterrez- Lobos KE, Lesch OM. Double-blind controlled trial of gammahydroxybutyrate and chlormethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 37, 67-73 (2002)
72. Ameisen O. Gamma-hydroxybutyrate deficiency in alcohol-dependence? Alcohol Alcohol. 42(5), 506 (2007)
73. Russell J, Perkins AT, Michalek JE et al.; the Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 60(1), 299-309 (2009)
74. Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: The use of drug therapies other than clonazepam. J. Clin. Sleep Med. 5(3), 235-239 (2009)
75. Khatami R, Tartarotti S, Siccoli MM, Bassetti CL, Śndor PS. Long-term efficacy of sodium oxybate in 4 patients with chronic cluster headache. Neurology 77(1), 67-70 (2011)
76. Ortega-Alb́s JJ, Díaz JR, López-Bernabé R, Vera JF, Alós M, Serrano AL. Treatment of Kleine-Levin syndrome with sodium oxybate. Sleep Med. 12(7), 730 (2011)
77. Lu J, Sherman D, Devor M, Saper C. A putative flip-flop switch for control of REM sleep. Nature 441, 589-594 (2007)
78. Zeitzer J, Buckmaster CL, Landolt H-P, Lyons D, Mignot E. Modafinil and g-hydroxybutyrate have sleep state-specific pharmacological actions on hypocretin-1 physiology in a primate model of human sleep. Behav. Pharmacol. 20(7), 643-652 (2009)
79. Fronczek R, Raymann RJEM, Romeijn N et al. Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep 31(2), 233-240 (2008)